Evidence map›Paper›PMID 29794151›Full record

ArticleDiabetes care2018

National Rates of Initiation and Intensification of Antidiabetic Therapy Among Patients With Commercial Insurance.

Lauren G Gilstrap, Ateev Mehrotra, Barbara Bai, Sherri Rose, Rachel A Blair, Michael E Chernew

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy.Diabetes spectrum : a publication of the American Diabetes Association · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lauren G GilstrapDepartment of Health Care Policy, Harvard Medical School, Boston, MA lgilstrap@bwh.harvard.edu.ORCID 0000-0003-2790-9428
Ateev MehrotraDepartment of Health Care Policy, Harvard Medical School, Boston, MA.
Barbara BaiDepartment of Health Care Policy, Harvard Medical School, Boston, MA.
Sherri RoseDepartment of Health Care Policy, Harvard Medical School, Boston, MA.
Rachel A BlairDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA.
Michael E ChernewDepartment of Health Care Policy, Harvard Medical School, Boston, MA.
Harvard University · USBrigham and Women's Hospital · USBeth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePrompt initiation and intensification of antidiabetic therapy can delay or prevent complications from diabetes. We sought to understand the rates of and factors associated with the initiation and intensification of antidiabetic therapy among commercially insured patients in the U.S. RESEARCH DESIGN AND

methodsUsing 2008-2015 commercial claims linked with laboratory and pharmacy data, we created an initiation cohort with no prior antidiabetic drug use and an HbA

resultsIn the initiation cohort (

conclusionsApproximately two-thirds of patients were newly initiated on antidiabetic therapy, and four-fifths of those already receiving antidiabetic therapy had it intensified within 6 months of an elevated HbA

Indexed as

AdolescentAdultAgedDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsInsuranceMaleMetforminMiddle AgedRetrospective StudiesUnited StatesGlycated HemoglobinHypoglycemic AgentsMetformin

Identifiers

PMID29794151
PMCPMC8742144
OpenAlexW2803993669

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.